Shui He
Head of Biometrics
pharmaceutical sciences
adc therapeutics
Netherlands
Biography
He is Head of Biometrics at ADC Therapeutics. Dr. He has experience in the pharmaceutical and biotechnology industries. Prior to joining ADC Therapeutics, Dr. He was Director of Biostatistics and Programming at Incyte Corporation, responsible for Jakafi ® (ruxolitinib), the first JAK inhibitor, submission for myelofibrosis, and polycythemia vera. Prior to Incyte Corporation, Dr. He held positions at Sanofi, where he played an important role in the development of Jevtana ® (cabazitaxel), Taxotere ® (Docetaxel). Dr. He is a graduate of the University of Pittsburgh, where he received his PhD in Biostatistics.
Research Interest
